Targets › PTH1R
8 programs from 8 companies in 9 trials: 4 Phase 4, 3 Phase 3, 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Other, Genitourinary; next expected readout Dec 2026.
G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP). (UniProt, Q03431)
Open in Phaseline: the race on PTH1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital for Special Surgery, New York | Abaloparatide Parathyroid hormone receptor agonist | PTH1R | Phase 4 | Osteoporosis, Postmenopausal; Spinal Fusion | Dec 2026 |
| Madhumathi Rao | Teriparatide Parathyroid hormone receptor agonist | PTH1R | Phase 4 | Age-Related Osteoporosis | Jan 2027 |
| Ditte Hansen | Teriparatide Parathyroid hormone receptor agonist | PTH1R | Phase 4 | Adynamic Bone Disease | Sep 2027 |
| Massachusetts General Hospital | Teriparatide Parathyroid hormone receptor agonist | PTH1R | Phase 4 | Osteoporosis, Postmenopausal | Nov 2027 |
| Ascendis Pharma Bone Diseases | Palopegteriparatide Parathyroid hormone receptor agonist | PTH1R | Phase 3 | Hypoparathyroidism | Jun 2027 |
| AstraZeneca | eneboparatide PTH1 receptor agonist (parathyroid hormone analog) | PTH1R | Phase 3 | Chronic Hypoparathyroidism | Jun 2027 |
| Ascendis Pharma | Palopegteriparatide Parathyroid hormone receptor agonist | PTH1R | Phase 3 | Hypoparathyroidism | Aug 2027 |
| National Institute of Dental and Craniofacial Research (NIDCR) | PTH-IA PTH1R inverse agonist, decreases proportion of mutant PTH1R receptors in active-state conf | PTH1R | Phase 1 | Jansen's Metaphyseal Chondrodysplasia | Jun 2029 |
Osteoporosis, Postmenopausal (2) Hypoparathyroidism (2) Spinal Fusion (1) Adynamic Bone Disease (1) Jansen's Metaphyseal Chondrodysplasia (1) Age-Related Osteoporosis (1) Chronic Hypoparathyroidism (1)
protein or peptide (4), mixed (3), small molecule (1)
Hospital for Special Surgery, New York (1) Ascendis Pharma Bone Diseases (1) Ascendis Pharma (1) Ditte Hansen (1) National Institute of Dental and Craniofacial Research (NIDCR) (1) Madhumathi Rao (1) Massachusetts General Hospital (1) AstraZeneca (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.